Brandl & Talos has advised the shareholders of Viennese biotech company Themis Bioscience GmbH on a Series C Financing Round. One of the shareholders, the Global Health Investment Fund, was also advised by DLA Piper, while Themis Bioscience was represented by Herbst Kinsky.
In addition to GHIF, the shareholders included– aws Grunderfonds, OMNES Capital, Ventech, Wellington Partners Life Sciences, and the Global Health Investment Fund.
According to a Brandl & Talos press release, Themis, which develops vaccines, "is considered a leader in the development of an active ingredient against Chikungunya virus, a serious disease with worldwide outbreak potential." The firm reports that, "with the investment of EUR 10 million, Themis aims to drive the development of clinical and pre-clinical vaccine development programs, including the most advanced vaccine against Chikungunya."
The Brandl & Talos team was led by Partner Roman Rericha, with the support of Lawyer Markus Arzt.
The DLA Piper team advising the Global Health Investment Fund was led by Partner Jasna Zwitter-Tehovnik, while the Herbst Kinsky team advising Themis Bioscience was led by Partner Florian Steinhart.
